Minsheng Securities Co., Ltd
About Guangzhou Jet Bio-Filtration Co.Ltd(688026) issuing convertible corporate bonds to unspecified objects
of
Listing recommendation
Sponsor (lead underwriter)
(No. 8, Puming Road, China (Shanghai) pilot Free Trade Zone)
February, 2002
Statement
The securities law of the people’s Republic of China, the securities recommendation law of the people’s Republic of China and the measures for the administration of listed companies (hereinafter referred to as “the securities recommendation law of the people’s Republic of China”) and the “law of the people’s Republic of China on the Administration of listed companies” The measures for the administration of securities issuance and registration of listed companies on the science and Innovation Board (for Trial Implementation) (hereinafter referred to as the “measures for the administration of registration”), the rules for the listing of shares on the science and Innovation Board of Shanghai Stock Exchange (hereinafter referred to as the “Listing Rules”) and other relevant laws and administrative regulations, as well as the relevant provisions of the China Securities Regulatory Commission (hereinafter referred to as the “CSRC”) and the Shanghai Stock Exchange, Be honest and trustworthy, be diligent and responsible, issue the listing recommendation letter in strict accordance with the business rules and industry self-discipline norms formulated according to law, and ensure that the documents issued are true, accurate and complete.
Unless otherwise specified, the abbreviations and terms used in this listing recommendation letter are consistent with the prospectus for Guangzhou Jet Bio-Filtration Co.Ltd(688026) issuing convertible corporate bonds to unspecified objects.
1、 Overview of the issuer (I) basic information
Chinese Name: Guangzhou Jet Bio-Filtration Co.Ltd(688026)
English Name: Guangzhou jet biofiltration Co., Ltd
Stock abbreviation: Guangzhou Jet Bio-Filtration Co.Ltd(688026)
Stock Code: 688026
Place of listing: Shanghai Stock Exchange
Registered capital: 100 million yuan
Legal representative: Yuan Jianhua
Secretary of the board of directors: Chen Changxi
Date of establishment of the company: April 11, 2001
Date of establishment of the joint stock company: November 7, 2014
Registered address: No. 1, doutang Road, Yonghe Economic Zone, Guangzhou Economic and Technological Development Zone
Office address: No. 1, doutang Road, Yonghe Economic Zone, Guangzhou Economic and Technological Development Zone
Postal Code: 511356
Tel: 020-32811888
Fax No.: 020-32811888-802
Internet address: http://www.jetbiofil.com.
Email: [email protected].
Unified social credit Code: 91440116728198443m
Plastic film manufacturing; Manufacturing of plastic products for medical and health use; Preparation of biodegradable plastic products; Experimental analysis instrument system; Preparation of drug detection instruments; Foam plastics; Made of daily plastic products; Mould making; New material technology development services; Biotechnology development services (rare and unique precious and fine varieties in China, except for the development of wildlife and plant resources protected by the state and originating in China); Manufacturing of chemical reagents and additives (except for MCCs and hazardous chemicals); Sales of chemical reagents and additives (except for MCCs and hazardous chemicals); Drug research and development (business scope of human stem cells and basic drugs: except for diagnosis and treatment technology); Operation of non licensed medical devices; Retail of medical supplies and equipment (excluding drugs and medical devices); Sell the products produced by the company (except for the items prohibited by national laws and regulations; the products involving licensed operation can be operated only after obtaining the license); Mold design and manufacture of non-metallic products; General labor protection articles system; House leasing; Site leasing (excluding warehousing); Technology import and export; Air pollution control; Import and export of goods (excluding goods involving special administrative provisions on foreign capital access and licensing approval); Development and production of new diagnostic reagents; Manufacture of medical laboratory equipment and instruments; Manufacturing of special labor protection articles
(II) main business
The company is a high-tech enterprise mainly engaged in the R & D, production and sales of cell culture and related liquid treatment biological laboratory consumables. Its main products include biological culture and liquid treatment biological laboratory consumables, and are equipped with a small amount of reagents and small laboratory instruments, involving more than 1000 products.
The company’s biological culture products can meet the requirements of cell culture of various types and different scales. Cell culture sectors, bottles and dishes provide space for cell growth and reproduction and culture surface; Liquid treatment is also one of the important links of cell culture. The company’s liquid treatment products mainly include pipette, centrifuge tube, filter, cryopreservation tube and suction head. Centrifuge tubes and filters are used for the separation and purification of functional products after cell culture; Cryopreservation tube is used for the preservation of cells and strains; Pipette is used for liquid transfer during cell culture; Micropipette, enzyme label sector, PCR reaction tube and other products are tools for immunological and molecular biological detection; Cell factory, 3D cell culture scaffold and perfusion culture device are used to meet the needs of large-scale cell culture.
The end customers of the company’s products mainly include biological laboratories in Colleges and universities, research institutions such as life sciences and medicine, disease control centers, inspection and quarantine institutions, drug and food monitoring institutions at all levels of the health and epidemic prevention system, central laboratories of medical institutions such as hospitals and clinics at all levels, pharmaceutical enterprises, biotechnology companies, etc. (III) core technology of the issuer
At present, the company has reached the leading level in China in the R & D, design and technical application of disposable plastic consumables in biological laboratory.
The company’s polymer material modification technology includes plasma treatment polymer material surface modification technology, plasma induced graft polymer material surface super hydrophilic modification technology, plasma induced graft polymer material surface super hydrophobic modification technology, polymer material temperature sensitive modification technology and 3D printing material modification technology for cell culture device.
The company’s polymer material processing technology mainly includes high-precision injection molding process and technology, high-speed and high-precision extrusion technology, 3D printing technology, perfusion control technology, pipette automatic production process and technology, plastic product filter membrane assembly technology, etc.
The company’s core technical features are as follows:
Type core technology name core technology overview
Using low-temperature plasma discharge to form cross-linked polymer materials under specific conditions, plasma treatment of polymer layers or generation of oxygen-containing functional groups such as carboxyl and hydroxyl groups, so that the surface of polymer material modification technology can obtain hydrophilic properties and form an ordinary hydrophilic surface with a contact angle of 30 ° – 40 °, The process is stable, the product is hydrophilic, and the shelf life can reach 3 years
Type core technology name core technology overview
The plasma treatment under specific conditions is used to generate self plasma initiated grafting high free radical on the material surface, and it is used as an initiator to induce super hydrophilic polymer monomer molecular material surface super hydrophilic graft copolymerization on the material surface, so as to obtain super hydrophilic high molecular modification technology chain on the material surface, The molecular chain can effectively prevent the adsorption of pollutants such as dust in the air and form a super hydrophilic surface with a contact angle of less than 10 ° and lasting stability
Treatment of raw materials at specific temperatures, plasma initiated grafting of highly separated daughters under inert gas atmospheres, and spraying of the original solution onto the surface of the base material surface by spray method, resulting in the formation of a nanostructured superhydrophobic layer on the surface of the substrate. The contact angle can reach more than 150 °, the material surface can reach low adsorption and low residue, and the micro pipetting accuracy is lower than 2.2 ‰
Taking advantage of the characteristics that the chemical structure of special compounds is composed of hydrophilic and hydrophobic parts and the critical phase transition temperature is 32 ℃, the temperature sensitive modification of polymer materials is realized through the change of temperature, so that the material surface can flexibly change to hydrophilic and hydrophobic.
Under the technical environment of 37 ° C, the surface can meet the in vitro culture and cell expansion of adherent cells. When the temperature is lower than 32 ° C, the cells can automatically fall off without damage, and the shedding rate can reach more than 90%
The modified technology of GPPS (highly transparent polystyrene) based printing material was studied by optimizing the modified formula in the cell culture device, and the modified material was prepared into 3D printing wire through special processing technology
The three-dimensional data modeling of the culture device can simulate the three-dimensional structure of fine 3D printing technology cells in animals and human bodies to the greatest extent. 3D printing materials are used to realize 4-layer or more hollow fiber cell culture scaffolds with fiber filaments with diameter of 150-500 µ m and pore diameter of 300 µ M
Based on the principles of liquid and gas dynamics, the culture device body is connected with the culture solution storage device through the pipeline and air filtration system. Under the condition that the peristaltic perfusion control technology pump provides power support, cells, gas exchange Culture medium and other essential elements of cell culture in vitro are in a controllable and closed circulating control system
350t full electric injection molding machine and needle valve hot runner mold are adopted. The injection speed is 500m / s and the injection molding time is 15s. Once the mold is out of 48 high-precision injection molding process and technical cavity, the surface of the produced cell culture sector, bottle and dish injection parts is smooth and there is no scratch under 40x microscope; The wall thickness of centrifugal pipe series is uniform, the tolerance of polymer materials is controlled within ± 0.05mm, and the centrifugal tolerance can reach 40000 G
After adopting the extrusion system, the wall thickness uniformity of the extruded pipette body can be effectively controlled by high-speed and high-precision extrusion, the wall thickness tolerance is controlled within ± 0.02mm, the technical defect rate is 5 ‰, the capacity accuracy is ± 1%, and the international standard is within ± 2%
The disposable serum pipette from the pipe extrusion, stretching, pipe cutting, silk screen printing, pipette automatic production, welding, leak detection, core plugging and packaging. The eight processes of the whole production line have realized the automation of technology and technology, and the production efficiency has been increased by 1.5 times; Effectively reduce the labor intensity of operators and reduce the working space for product processing
